Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2014. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) connected to the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding specific share plan transactions rather than a financial results report.
Material Changes
The filing details an increase in the notional allocation of American Depositary Shares (ADSs) within the GSK 401K plan following a revaluation of the cash element. The transaction occurred on January 3, 2014, at a price of $52.80 per ADS.
- Dr M M Slaoui: Received 16 ADSs.
- Dr K Slaoui: Received 4 ADSs.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Investor Verification Points
- Verify the impact of the $52.80 ADS price on the notional holdings of the GSK 401K plan.
- Confirm the specific roles of Dr M M Slaoui and Dr K Slaoui as Directors/PDMRs.
- Note that this filing does not contain operational or financial performance data for the period.